Riluzol PMCS 50 mg is an oral neuroprotective medication used in the management of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder affecting motor neurons. The active substance, riluzole, helps slow the progression of the disease by reducing neuronal damage associated with excitatory neurotransmitters.
Although not a cure, riluzole is widely used as part of standard therapy to help extend survival and delay disease-related complications in patients with ALS.
Riluzole acts primarily by modulating glutamate activity in the central nervous system. Excess glutamate is believed to contribute to neuronal damage in ALS. The drug inhibits glutamate release, blocks voltage-dependent sodium channels, and interferes with excitatory signaling pathways, helping protect motor neurons from degeneration.
Riluzol PMCS 50 mg is indicated for:
Use should be initiated and monitored by a healthcare professional.
Do not exceed the prescribed dose without medical supervision.
Common side effects may include:
Less common but serious effects may occur and require medical attention.
What is Riluzole used for?
Riluzole is used to treat amyotrophic lateral sclerosis and helps slow disease progression.
Does Riluzole cure ALS?
No, it does not cure ALS but may extend survival and delay complications.
How does it work?
It reduces glutamate-related nerve damage and protects motor neurons.
How long should it be taken?
Treatment duration is determined by a healthcare provider and often continues long-term.
Riluzole has been a cornerstone in ALS treatment for many years and remains one of the most widely used medications for managing this condition. Its neuroprotective properties make it an important option in slowing disease progression.
This content is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using this medication.
Ask a question or inquire about delivery to your country


